Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of “Moderate Buy” by Brokerages

Beta Bionics, Inc. (NASDAQ:BBNX) has received an average rating of “Moderate Buy” from the thirteen analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $29.40.

Several equities research analysts have recently weighed in on BBNX shares. Bank of America cut Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. Lake Street Capital lifted their target price on Beta Bionics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Truist Financial increased their price target on Beta Bionics from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday, December 29th. Finally, Robert W. Baird set a $28.00 price objective on Beta Bionics in a report on Tuesday, December 16th.

Beta Bionics Price Performance

Shares of Beta Bionics stock opened at $18.50 on Thursday. The firm has a market cap of $814.56 million and a price-to-earnings ratio of -4.23. Beta Bionics has a 52-week low of $8.89 and a 52-week high of $32.71. The stock has a 50-day simple moving average of $28.20 and a 200-day simple moving average of $22.52.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%. The business had revenue of $27.25 million during the quarter, compared to analyst estimates of $23.92 million.

Insider Activity at Beta Bionics

In other Beta Bionics news, insider Mike Mensinger sold 7,800 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.61, for a total transaction of $230,958.00. Following the completion of the transaction, the insider owned 82,952 shares in the company, valued at approximately $2,456,208.72. This represents a 8.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen Feider sold 20,000 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the sale, the chief financial officer directly owned 42,614 shares in the company, valued at approximately $1,258,391.42. This represents a 31.94% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 35,302 shares of company stock worth $1,036,449.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BBNX. Vanguard Group Inc. lifted its holdings in Beta Bionics by 213.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after purchasing an additional 1,509,217 shares during the last quarter. Divisadero Street Capital Management LP bought a new position in shares of Beta Bionics in the second quarter valued at about $13,817,000. Sands Capital Alternatives LLC lifted its stake in shares of Beta Bionics by 15.0% during the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock worth $51,981,000 after buying an additional 466,331 shares during the last quarter. Soleus Capital Management L.P. boosted its holdings in shares of Beta Bionics by 12.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after buying an additional 424,817 shares during the period. Finally, Pura Vida Investments LLC grew its stake in Beta Bionics by 11,150.0% in the 3rd quarter. Pura Vida Investments LLC now owns 281,250 shares of the company’s stock valued at $5,588,000 after buying an additional 278,750 shares during the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.